News from the healthcare data industry
April 20, 2022 In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world...
April 20, 2022 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp. Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use in Long COVID Patients with Multi-Site...
Abstract Daratumumab monotherapy was first investigated in GEN501 and SIRIUS trials in relapsed/refractory multiple myeloma (RRMM) patients, showing positive results. However, there is a lack of information on plasmacytoma response....
Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial. A real-world analysis evaluating the triplet regimen...
ABSTRACT BACKGROUND: It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression...
ABSTRACT BACKGROUND AND AIMS: The impact of the COVID-19 pandemic on patients with inflammatory bowel disease [IBD] is largely unknown. We characterized the impact of COVID-19 on IBD care by...
April 08, 2022 04:01 PM Eastern Daylight Time OXFORD, England & VIENNA, Austria–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer...
Dive Brief: The Food and Drug Administration has approved the first drug to treat an ultra-rare cluster of conditions caused by mutations in a specific gene, granting an accelerated clearance to...
New research published in The BMJ indicates the introduction of low dose CT (LDCT) screening in 2013 coincided with improved survival and a shift toward diagnoses of stage I non–small cell lung...
Sickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Patients from French Guiana and Qatar were Few and Mild TORRANCE,...